STOCKS TELEGRAPH

Tag: BXRX

  • Baudax Bio Inc. (BXRX) stock Plummets Premarket Following Pricing of $10M Public Offering

    Baudax Bio Inc. (BXRX) stock Plummets Premarket Following Pricing of $10M Public Offering

    On February 24, Baudax Bio Inc. (BXRX) announced the pricing of a $10.0 million public offering. Following this, the stock plunged deep in the premarket on Friday.

    During the regular session, the stock enjoyed a profit of 12.89% as it added $0.50. At an above-average volume of 306.34K shares, BXRX stock closed the session at $4.38. While the stock did make some good gains, it reported its new 52-week low of $3.6030 during the regular session. Following the public offering, BXRX stock plunged deep in the premarket to reach a value of $2.00 per share. At the time of writing, the stock had subtracted a huge 54.33% in the premarket on Friday. Thus, BXRX had gone down by $2.38, at the last check, in the premarket.

    The pharmaceutical company, Baudax Bio Inc. has a market capitalization of $9.38 million. Currently, the company has 2.42 million shares outstanding in the market. BXRX stock went down by a humungous 90.73% last year and has lost 42.91% year to date.

    BXRX’s Public Offering

    On Thursday, the company announced the pricing of its underwritten public offering of 3,508,772 common stock shares and warrants. The combined public offering price of a common stock share together with a warrant for buying a common stock share is $2.85 per share. Moreover, the exercise price of the warrants is $3.25 per share and has five-year expiry following the issuance date. The expected gross proceeds from the offering are $10.0 million, less commission, and discounts.

    Additionally, BXRX has also granted an option for buying additional 526,315 common stock shares and/or warrants for the same.

    The company intends to use the net proceeds from the offering for general corporate purposes along with pipeline development including ANJESO commercialization.

    Reverse Stock Split

    On February 15, the company announced the approval of a 1-for-35 reverse stock split of common shares by its board. The stock split became effective at 12:01 am EST on February 16, 2022. This reverse stock split was also approved by the shareholders on February 09, 2022, during a special meeting.

    Furthermore, the purpose of the stock split was to bring the company into compliance with Nasdaq’s minimum bid price by increasing the per-share price.

    BXRX’s Financials

    In Q3 2021, the company had net product revenue of $0.3 million against $0.1 million in the year-ago quarter.

    BXRX had a net loss of $17.0 million or $0.20/diluted share in the third quarter of 2021.

    The company ended the quarter with cash, cash equivalents, and short-term investments of $24.9 million.

  • Baudax Bio Inc. (BXRX) stock Rebounds Premarket. Here is what’s happening?

    On January 20, shares of Baudax Bio Inc. (BXRX) skyrocketed in the premarket session to reach $0.27 at the last check. No official news from the company seems to be driving the stock up.

    During regular trading, the stock saw a high of $0.2149 and a low of $0.1900. BXRX closed the session at $0.1964 with 5.84 million shares exchanging. The stock soon saw a reversal as it entered the premarket session. Hence, BXRX had added a huge 39.96% in the premarket at the time of writing.

    The pharmaceutical company, Baudax Bio Inc. was founded in 2015. Currently, its 84.58 million outstanding shares trade at a market capitalization of $17.24 million.

    BXRX’s Recovery and Movement

    BXRX stock had been gloomy for a few days. After losing 7.36% in the past five days, the stock finally recovered in today’s premarket session. There are no recent news or SEC filings from the company that might indicate the reason for the upsurge. Although, the company does have an upcoming event. The company will be holding a special meeting of shareholders on February 09, 2022.

    This depicts that the stock may be moving up due to some external factors like investors’ interest based on social media platforms or the low in the price being a good buying opportunity, etc.

    Overall, BXRX stock has lost 10.40% year to date while it subtracted a huge 88.45% last year.

    Recent Developments

    Recently, the company participated in the H.C. Wainwright BioConnect Virtual Conference which took place from January 10 to 13, 2022. The company’s President and Chief Executive Officer, Gerri Henwood presented at the conference.

    BXRX’s Inducement Grant

    On December 31, the company announced awarding inducements grants to 14 newly-hired employees, with a grant date of December 29, 2021. Moreover, BXRX’s Board’s Compensation Committee approved the grants. Under these grants stock options of buying 109,250 of the company’s common stock hares and restricted stock units covering 31,900 shares, were awarded.

    In addition, as per the closing price on December 29, the exercise price of these options is $0.22 per share.

    Financial Details

    On November 04, 2021, the company declared its financial results for the third quarter of 2021.

    In the third quarter of 2021, BXRX reported net product revenue of $0.3 million against $0.1 million in the year-ago quarter.

    Moreover, the company suffered from a net loss of $17.0 million in Q3 of 2021, against an adjusted net loss of $11.3 million in Q3 of 2020. This also included a $5.7 million non-cash charge. Resultantly, the net loss per diluted share was $0.20 in the third quarter of 2021.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.